Sam­sung Bi­o­log­ics se­cures $400M+ man­u­fac­tur­ing deal with Pfiz­er

Sam­sung Bi­o­log­ics struck a deal with Pfiz­er to man­u­fac­ture the drug­mak­er’s biosim­i­lars port­fo­lio, in­clud­ing its prod­ucts for im­munol­o­gy, in­flam­ma­tion and on­col­o­gy, the South Ko­re­an com­pa­ny …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER